查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933365

全球膀胱癌疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Bladder Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

膀胱癌疫苗市场成长因素

预计2025年全球膀胱癌疫苗市场规模将达到3,504.6亿美元，2026年将成长至4174.3亿美元，2034年将达到24,233.7亿美元，预测期内复合年增长率（CAGR）为24.59%。欧洲在2025年将占市场主导地位，市场占有率达36.31%，这主要归功于膀胱癌的高发病率、完善的医疗保健基础设施以及治疗性疫苗的日益普及。膀胱癌是全球最常见的癌症之一，卡介苗 (BCG) 疫苗可有效治疗，主要用于非肌肉层浸润性膀胱癌 (NMIBC)。膀胱癌发病率的上升以及生活方式相关的风险因素，例如长期接触致癌物和吸烟，正在推动全球对膀胱癌疫苗的需求。

默克、盐野义製药株式会社和 ImmunityBio, Inc. 等领先企业正在大力投资研发，并扩大其全球业务，以巩固其市场地位。持续的创新和新的在研产品正在推动成长，确保未来十年市场前景稳健。

市场动态

成长因素：膀胱癌发生率的上升是推动成长的关键因素。根据世界癌症研究基金会 (WCRF) 2022 年的报告，预计全球新增膀胱癌病例将达到 614,289 例，凸显了治疗介入的紧迫性。医疗机构扩大采用卡介苗 (BCG) 疫苗治疗早期非肌肉层浸润性膀胱癌 (NMIBC)，这正在推动市场需求。

市场限制因素：目前，缺乏替代疫苗疗法是限制市场发展的主要因素。卡介苗是目前唯一获准用于治疗膀胱癌的疫苗，但正如膀胱癌倡导网络 (Bladder Cancer Advocacy Network) 在 2020 年报告的那样，供应短缺和效率低下可能会限制患者获得疫苗的机会，并抑制市场成长。

机会：专注于新型候选疫苗的研发 (R&D) 蕴藏着巨大的商机。下一代疫苗旨在提高安全性、易用性和有效性。例如，盐野义製药株式会社于2021年完成了其S-588410癌症胜肽疫苗的II期临床试验，展现了治疗研发领域的创新。

挑战：临床试验的高失败率阻碍了成长。肿瘤异质性和免疫反应的变异性使有效膀胱癌免疫疗法的研发变得复杂。延迟和供应链挑战，例如Ferring Pharmaceuticals在2024年遇到的情况，影响了及时供应和分销。

市场趋势

一个重要的趋势是疫苗和免疫疗法的整合。联合疗法正被越来越多地用于促进免疫活化并降低对卡介苗（BCG）无反应患者的復发率。 2024年4月，美国食品药物管理局 (FDA) 批准了诺加潘地喹α/invaxcept-PMLN 与卡介苗 (BCG) 联合用于治疗对 BCG 治疗无效的非肌肉层浸润性膀胱癌 (NMIBC) 患者。这项疗法正在重塑治疗方案，并推动市场扩张。

市场区隔分析

依产品划分：BCG 疫苗占市场主导地位，是目前唯一获得商业核准的治疗性疫苗。策略联盟，例如 ImmunityBio 与印度血清研究所于 2024 年 5 月达成的协议，将支持下一代重组 BCG 疫苗的研发，用于 ANKTIVA 等联合疗法。

依给药途径划分：膀胱内给药途径占领先地位，该途径透过标靶递送降低全身毒性和肿瘤復发率。 RUTIVAC-1 研究（EAU25，2025）的临床证据表明，膀胱内注射卡介苗可增强免疫反应。

依分销管道划分：由于需要经认证的医疗监督，医院是膀胱内给药的主要管道。 ImmunityBio 与 Urology Partners 达成的 2025 年合作协议等合作项目，有助于解决供应短缺问题，并加强医院分销。

区域展望

欧洲：预计 2025 年欧洲市场规模将达到 1,272.6 亿美元，在高发病率和研究计画的推动下，欧洲市场将引领成长。 2025 年，欧洲将通报超过 22.4 万例膀胱癌新病例，其中光是欧盟就将有 16.5 万例。

北美：先进的医疗基础设施预计将支持卡介苗的普及，推动市场以 31.3% 的复合年增长率成长。预计到 2034 年，诊断技术的发展以及持续的研发将推动市场规模达到 9,300 万美元。

亚太地区：中国和印度膀胱癌发病率的上升以及医疗保健的不断扩展，使该地区成为第三大市场。

拉丁美洲、中东和非洲：由于膀胱癌发病率的上升以及对有效疫苗需求的增长，预计该地区将保持温和增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区膀胱癌盛行率（2025 年）
  • 主要国家及地区监理概况
  • 主要公司研发管线分析
  • 关键趋势：併购、业务合作、新产品发布、核准等

第五章：全球膀胱癌癌症疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品分类
    • 卡介苗 (BCG)
    • 其他
  • 市场分析、洞察与预测：依给药途径分类
    • 膀胱内给药
    • 其他
  • 市场分析、洞察与预测：依通路分类
    • 医院
    • 政府及机构供应
    • 其他
  • 市场分析、洞察与预测：依地区分类
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美膀胱癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲膀胱癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区膀胱癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 中国
    • 日本
    • 印度
    • 东南亚
    • 澳大利亚
    • 亚太其他地区

第九章：拉丁美洲膀胱癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲膀胱癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家
    • 南非
    • 中东其他地区非洲

第11章 竞争分析

  • 全球市场占有率分析(2025年)
  • 企业简介
  • Merck &Co., Inc.,
  • Shionogi &Co., Ltd.
  • ImmunityBio, Inc.
  • Altor BioScience, LLC
  • Hamlet BioPharma.
  • Asieris Pharmaceuticals.
  • Pfizer Inc.
Product Code: FBI113882

Growth Factors of bladder cancer vaccines Market

The global bladder cancer vaccines market was valued at USD 350.46 billion in 2025 and is projected to grow to USD 417.43 billion in 2026, eventually reaching USD 2,423.37 billion by 2034, exhibiting a CAGR of 24.59% during the forecast period. Europe dominated the market in 2025 with a 36.31% share, driven by the high prevalence of bladder cancer, established healthcare infrastructure, and increased adoption of therapeutic vaccines. Bladder cancer, one of the most prevalent cancers worldwide, can be treated effectively with Bacillus Calmette-Guerin (BCG) vaccines, primarily for non-muscle invasive bladder cancers (NMIBCs). Rising incidence rates and lifestyle-related risk factors, such as prolonged exposure to carcinogens and smoking, are fueling the demand for bladder cancer vaccines globally.

Leading players, including Merck & Co., Inc., Shionogi & Co., Ltd., and ImmunityBio, Inc., are investing heavily in research and development (R&D) and expanding their global presence to strengthen their market positions. Continuous innovations and new pipeline candidates are driving growth, ensuring a robust market outlook for the coming decade.

Market Dynamics

Drivers: The increasing prevalence of bladder cancer is the primary growth driver. According to the World Cancer Research Fund 2022, there were 614,289 new bladder cancer cases globally, reflecting the urgent need for therapeutic interventions. Healthcare providers are increasingly adopting BCG vaccines for early-stage NMIBCs, boosting market demand.

Restraints: The market is currently constrained by the lack of alternative vaccine treatments. BCG remains the only approved vaccine for bladder cancer, and shortages or inefficiencies, such as those reported by the Bladder Cancer Advocacy Network in 2020, may limit patient access and restrict growth.

Opportunities: Emphasis on R&D for new vaccine candidates presents lucrative opportunities. Next-generation vaccines aim to improve safety, ease of administration, and efficacy. For example, Shionogi & Co., Ltd. completed a Phase II study of the S-588410 cancer peptide vaccine in 2021, showcasing innovation in therapeutic development.

Challenges: High clinical trial failures hamper growth. Tumor heterogeneity and variable immune responses make developing effective bladder cancer immunotherapies complex. Delays and supply chain challenges, such as those experienced by Ferring Pharmaceuticals in 2024, impact timely availability and adoption.

Market Trends

A key trend is the integration of vaccines with immunotherapies. Patients unresponsive to BCG are increasingly receiving combination treatments to enhance immune activation and reduce relapse rates. In April 2024, the FDA approved Nogapendekin alfa inbakicept-pmln with BCG for BCG-unresponsive NMIBC patients. This approach is reshaping treatment protocols and supporting market expansion.

Segmentation Analysis

By Product: The BCG segment dominates the market, being the only commercially approved therapeutic vaccine. Strategic partnerships, such as ImmunityBio's collaboration with the Serum Institute of India in May 2024, support next-generation recombinant BCG development for combination therapies like ANKTIVA.

By Route of Administration: The intravesical segment leads due to its targeted delivery, reducing systemic toxicity and lowering tumor recurrence. Clinical evidence from the RUTIVAC-1 Trial (EAU25, 2025) demonstrates enhanced immune response when BCG is administered intravesically.

By Distribution Channel: Hospitals dominate due to certified medical supervision required for intravesical administration. Collaborations, such as ImmunityBio's partnership with U.S. Urology Partners in 2025, address shortages and reinforce hospital-based distribution.

Regional Outlook

Europe: Led the market in 2025 with USD 127.26 billion, driven by high incidence and research initiatives. Over 224,000 new bladder cancer cases were reported in Europe in 2025, with 165,000 in the EU alone.

North America: Projected to grow at 31.3% CAGR, with advanced healthcare infrastructure supporting adoption. The region is expected to reach USD 93.0 million by 2034, driven by diagnostics and ongoing R&D.

Asia Pacific: Positioned as the third-largest market due to rising prevalence and healthcare expansion in China and India.

Latin America & Middle East & Africa: Moderate growth is anticipated due to increasing bladder cancer incidence and demand for effective vaccines.

Competitive Landscape

The market is concentrated, dominated by Merck & Co., Shionogi & Co., ImmunityBio, Altor BioScience, and others. These companies leverage R&D, collaborations, and global distribution to strengthen their positions. Notable developments include:

  • August 2025: Hamlet BioPharma completed Phase II alpha1h study in NMIBC patients.
  • January 2025: Pfizer's Phase III CREST trial evaluated sasanlimab with BCG for high-risk NMIBC.
  • July 2025: ImmunityBio received UK MHRA approval for ANKTIVA combined with BCG.

Conclusion

The global bladder cancer vaccines market is set to grow from USD 350.46 billion in 2025 to USD 417.43 billion in 2026, reaching USD 2,423.37 billion by 2034 at a CAGR of 24.59%. Europe remains the dominant region, supported by rising prevalence and extensive research initiatives. Growth is fueled by the increasing burden of bladder cancer, strategic partnerships, combination therapies, and the development of next-generation vaccines. Despite challenges such as clinical trial failures and reliance on BCG, ongoing R&D and immunotherapy integrations are expected to drive substantial advancements, making the market highly promising for key players and new entrants alike.

Segmentation By Product

  • Bacillus Calmette-Guerin (BCG)
  • Others

By Route of Administration

  • Intravesical
  • Others

By Distribution Channel

  • Hospitals
  • Government & Organization Supply
  • Others

By Geography

  • North America (By Product, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Bladder Cancers, by Key Countries/ Region, 2025
  • 4.2. Overview of Regulatory Scenario by Key Countries/Regions
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions, Partnerships, Launches, Approvals, etc.

5. Global Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Bacillus Calmette-Guerin (BCG)
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Intravesical
    • 5.2.2. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospitals
    • 5.3.2. Government & Organization Supply
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Bacillus Calmette-Guerin (BCG)
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Intravesical
    • 6.2.2. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospitals
    • 6.3.2. Government & Organization Supply
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Bacillus Calmette-Guerin (BCG)
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Intravesical
    • 7.2.2. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospitals
    • 7.3.2. Government & Organization Supply
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Bacillus Calmette-Guerin (BCG)
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Intravesical
    • 8.2.2. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospitals
    • 8.3.2. Government & Organization Supply
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Southeast Asia
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Bacillus Calmette-Guerin (BCG)
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Intravesical
    • 9.2.2. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospitals
    • 9.3.2. Government & Organization Supply
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Bacillus Calmette-Guerin (BCG)
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Intravesical
    • 10.2.2. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospitals
    • 10.3.2. Government & Organization Supply
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Merck & Co., Inc.,
    • 11.2.2. Shionogi & Co., Ltd.
    • 11.2.3. ImmunityBio, Inc.
    • 11.2.4. Altor BioScience, LLC
    • 11.2.5. Hamlet BioPharma.
    • 11.2.6. Asieris Pharmaceuticals.
    • 11.2.7. Pfizer Inc.

List of Tables

  • Table 1: Global Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 2: Global Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 5: North America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 6: North America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country, 2021-2034
  • Table 9: Europe Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 10: Europe Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 14: Asia Pacific Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 17: Latin America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 18: Latin America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 22: Middle East & Africa Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Bladder Cancer Vaccines Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Bladder Cancer Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Bladder Cancer Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 7: North America Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 8: North America Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 9: North America Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Bladder Cancer Vaccines Market Value (USD million), by Country, 2025 & 2034
  • Figure 13: North America Bladder Cancer Vaccines Market Value Share (%), by Country, 2025
  • Figure 14: Europe Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 15: Europe Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 16: Europe Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Bladder Cancer Vaccines Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Bladder Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Bladder Cancer Vaccines Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Bladder Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 31: Latin America Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 32: Latin America Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Bladder Cancer Vaccines Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Bladder Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 39: Middle East & Africa Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 40: Middle East & Africa Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Bladder Cancer Vaccines Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Bladder Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Bladder Cancer Vaccines Market Share (%), by Company, 2025